Tag: Long-acting amylin analog

  • Cagrilintide

    Long-acting amylin analog

    A long-acting amylin analog with attached fatty acid for albumin binding; under development as an obesity treatment in combination with semaglutide.

    Abstract

    Cagrilintide (CAS 1415456-37-9; modified amylin analog with C18 fatty acid attached at lysine for albumin binding; molecular weight approximately 4870 Da) is a long-acting amylin receptor agonist developed by Novo Nordisk for obesity. The compound is structurally derived from pramlintide with addition of a C18 fatty acid linker for albumin binding (the same long-acting strategy as semaglutide), extending plasma half-life from less than 1 hour for amylin to approximately 7 days for cagrilintide. Phase 1 and 2 trials in obesity demonstrated dose-dependent weight loss; in combination with semaglutide (the CagriSema combination), phase 2 trials showed up to 17 percent body weight loss at 32 weeks, approaching the magnitude of bariatric surgery. Phase 3 trials (REDEFINE program) are ongoing. Plasma half-life supports once-weekly subcutaneous dosing. Used as the prototype long-acting amylin agonist in metabolic research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.